NOVEMBER 20256EUROPEAcross Europe, four once-separate capabilities now function like a single system: digital epigenetic mapping that sharpens hypotheses, consulting that translates signals into regulatory routes, stem cell banks that standardise inputs, and transient protein expression that tests ideas in material. Together they turn discovery into something usable. Discovery becomes evidence. Evidence becomes access.Digital epigenetic mapping shows how cells change, flags biomarkers, and tightens hypotheses that matter in real trials. Consulting teams then convert those signals into regulatory roadmaps and HTA narratives for EU and UK review. Stem cell banks supply well-characterised lines so researchers adopt shared standards and achieve reproducibility across borders. Transient expression in HEK and CHO produces proteins quickly for assays and early leads, closing the loop between omics and function.Friction persists. Data silos and divergent sharing rules make clean multi-country datasets slow to build. Regulations shift and jurisdictional differences add drag for biologics and digital-health programmes. Stem cell oversight varies by nation, creating uncertainty for cross-border sourcing. In the lab, transient expression still struggles with yield, stability, and scale-up.Progress is visible. The European Health Data Space is promoting common data models and privacy-preserving exchange. Specialist consulting pre-aligns endpoints, real-world evidence, and AI documentation with current expectations to avoid late surprises. Ethical harmonisation and transparent consent are strengthening trust in stem cell banking and expanding access to standardised lines. In parallel, better vectors, tuned media, and engineered cell lines are lifting consistency and speed.Taken together, these moves are knitting Europe into a more connected ecosystem where high-quality insight, reliable materials, and faster expression are aligned, and strong science advances toward patients with greater confidence.In this edition, we feature firms and individuals shaping these markets, including Precision Antibody, a leading biotechnology company specialising in high-affinity custom antibody development. We also include insights from Marcelo Vaz, Vice President, Medical Services at TMC Pharma Services, and Stefano Ferrara, Director of Clinical Science at BeiGene, offering a panoramic market view and helping you make more data-driven business decisions. Let us know your thoughts!EDITORIALCollaboration across Europe's Advanced Life SciencesCopyright © 2025 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.com NOVEMBER 2025, Vol 06, Issue - 30 (ISSN 2831-8331) Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com Editorial StaffAaron PierceCarolynn WaltersShirley FaithRussell ThomasVisualizersPresley MeadowDisclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsHenry SmithClara Matthew
< Page 5 | Page 7 >